Ticker
ACHV

Price
4.83
Stock movement up
+0.12 (2.55%)
Company name
Achieve Life Sciences Inc
Exchange
(NASDAQ
,
Currency
USD
)
Sector
Healthcare >
Biotechnology
Market cap
46.76M
Ent value
29.61M
Price/Sales
-
Price/Book
2.18
Div yield
-
Div growth
-
Growth years
-
FCF payout
-
Trailing P/E
-
Forward P/E
-
PEG
-
EPS growth
-
1 year return
-35.86%
3 year return
-50.07%
5 year return
-61.29%
10 year return
-58.46%
Last updated: 2022-08-25

DIVIDENDS

ACHV does not pay dividends

VALUATION

Valuation Ratios

Loading...
Valuation Ratios data
Trailing P/E-
Price to OCF-
Price to FCF-
Price to EBITDA-
EV to EBITDA-

Valuation (Sales/Book Value)

Loading...
Valuation (Sales/Book Value) data
Price to Sales-
Price to Book2.18
EV to Sales-

FINANCIALS

Per share

Loading...
Per share data
Current share count9.68M
EPS (TTM)-3.46
FCF per share (TTM)-3.15

Income statement

Loading...
Income statement data
Revenue (TTM)0.00
Gross profit (TTM)0.00
Operating income (TTM)-32.34M
Net income (TTM)-32.73M
EPS (TTM)-3.46
EPS (1y forward)-2.87

Margins

Loading...
Margins data
Gross margin (TTM)-
Operating margin (TTM)-
Profit margin (TTM)-

Balance Sheet

Loading...
Please create a free account or log in to access this chart
Balance Sheet data
Cash36.34M
Net receivables0.00
Total current assets37.69M
Goodwill1.03M
Intangible assets1.59M
Property, plant and equipment0.00
Total assets40.61M
Accounts payable418.00K
Short/Current long term debt15.23M
Total current liabilities4.01M
Total liabilities19.18M
Shareholder's equity21.43M
Net tangible assets18.81M

Cash flow

Loading...
Please create a free account or log in to access this chart
Cash flow data
Operating cash flow (TTM)-29.77M
Capital expenditures (TTM)0.00
Free cash flow (TTM)-29.77M
Dividends paid (TTM)0.00

Financial returns

Loading...
Please create a free account or log in to access this chart
Financial returns data
Return on Equity-152.69%
Return on Assets-80.58%
Return on Invested Capital-89.41%
Cash Return on Invested Capital-81.32%

STOCK INFORMATION

Stock chart

Loading...
Stock price data
Open4.73
Daily high4.87
Daily low4.49
Daily Volume127K
All-time high1821600.00
1y analyst estimate31.75
Beta1.20
EPS (TTM)-3.46
Dividend per share-
Ex-div date-
Next earnings date7 Nov 2022

Downside potential

Loading...
Downside potential data
ACHVS&P500
Current price drop from All-time high-100.00%-13.41%
Highest price drop-100.00%-56.47%
Date of highest drop24 Aug 20229 Mar 2009
Avg drop from high-88.01%-11.38%
Avg time to new high91 days12 days
Max time to new high6258 days1805 days
COMPANY DETAILS
ACHV (Achieve Life Sciences Inc) company logo
Marketcap
46.76M
Marketcap category
Small-cap
Description
Achieve Life Sciences, Inc., a clinical-stage pharmaceutical company, develops and commercializes of cytisinicline for smoking cessation and nicotine addiction in Canada, the United States, and the United Kingdom. The company offers cytisinicline, a plant-based alkaloid that interacts with nicotine receptors in the brain that reduce the severity of nicotine withdrawal symptoms. It has license agreements with Sopharma AD and University of Bristol. The company is based in Vancouver, Canada.
Employees
16
Investor relations
-
SEC filings
CEO
Richard Alistair Balfour Stewart
Country
USA
City
Vancouver
Stock type
Common stock
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
All newsPress releases
ORCA-3 Designed to Enable FDA Registration and Confirm the Efficacy and Safety of 3 mg Cytisinicline Three Times Daily Dosing Compared to Placebo in Adult Smokers in the United StatesSEATTLE, Wash and...
September 27, 2022
SEATTLE and VANCOUVER, British Columbia, Sept. 07, 2022 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (NASDAQ: ACHV), a late-stage clinical pharmaceutical company committed to the global development...
September 7, 2022
By John Vandermosten, CFA NASDAQ:ACHV READ THE FULL ACHV RESEARCH REPORT Second Quarter 2022 Results Achieve Life Sciences, Inc. (NASDAQ:ACHV) reported second quarter 2022 results in a press release a...
August 15, 2022
Company to host conference call at 4:30 PM EDT today, August 11, 2022SEATTLE and VANCOUVER, British Columbia, Aug. 11, 2022 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (NASDAQ: ACHV), a late-stage...
August 11, 2022
SEATTLE and VANCOUVER, British Columbia, July 28, 2022 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (NASDAQ: ACHV), a late-stage clinical pharmaceutical company committed to the global development ...
July 28, 2022
SEATTLE and VANCOUVER, British Columbia, July 01, 2022 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage pharmaceutical company committed to the global development and comme...
July 1, 2022
SEATTLE and VANCOUVER, British Columbia, June 29, 2022 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage pharmaceutical company committed to the global development and comme...
June 29, 2022
SEATTLE and VANCOUVER, British Columbia, June 21, 2022 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (NASDAQ: ACHV), a late-stage clinical pharmaceutical company committed to the global development ...
June 21, 2022
Company awarded $2.5 million to enable initiation of the Phase 2 ORCA-V1 clinical trialSEATTLE and VANCOUVER, British Columbia, June 01, 2022 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (NASDAQ: A...
June 1, 2022
SEATTLE and VANCOUVER, British Columbia, May 26, 2022 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (NASDAQ: ACHV), a clinical-stage pharmaceutical company committed to the global development and co...
May 26, 2022
Next page